Topic: α-synuclein pre-formed fibrils

Parkinson's disease (PD) is a multifaceted neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, predominantly within the substantia nigra pars compacta (SNc) region. Dysregulation of FoxO1 has been implicated in various neurodegenerative diseases, including Alzheimer's disease and PD, yet the precise underlying mechanisms remain largely elusive. In this study, we investigated the impact of α-synuclein pre-formed fibrils (PFF) treatment on BV-2 microglial cells to elucidate alterations in molecular properties and neuronal degeneration. Surprisingly, our find

Lund Human Mesencephalic (LUHMES) cells are a cellular model of Parkinson’s disease (PD) that can be grown as undifferentiated cells and be differentiated into dopaminergic neurons. Here we have identified a series of changes in mitochondrial phenotypes that occur throughout the differentiation process and need to be considered when using this model in a PD context. Besides the acquisition of a neuronal dopaminergic phenotype with increased levels of tyrosine hydroxylase, dopamine receptor D2 or β-III-tubulin, we identified changes in mitochondrial markers reflecting an important reduction in